BioCardia (NASDAQ:BCDA) versus Appili Therapeutics (OTCMKTS:APLIF) Financial Survey

Appili Therapeutics (OTCMKTS:APLIF) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Appili Therapeutics and BioCardia, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Appili Therapeutics	0	0	0	0	N/A
BioCardia	0	0	1	0	3.00

BioCardia has a consensus price target of $25.00, suggesting a potential upside of 861.54%. Given BioCardia’s higher possible upside, analysts clearly believe BioCardia is more favorable than Appili Therapeutics.

Risk and Volatility

Appili Therapeutics has a beta of -0.48, suggesting that its share price is 148% less volatile than the S&P 500. Comparatively, BioCardia has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500.

Earnings and Valuation

This table compares Appili Therapeutics and BioCardia”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Appili Therapeutics	$630,000.00	5.77	-$2.80 million	($0.03)	-1.00
BioCardia	$428,000.00	11.06	-$11.57 million	($7.05)	-0.37

Appili Therapeutics has higher revenue and earnings than BioCardia. Appili Therapeutics is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Appili Therapeutics and BioCardia’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Appili Therapeutics	-450.64%	N/A	-186.27%
BioCardia	-1,999.77%	N/A	-278.27%

Institutional and Insider Ownership

20.6% of BioCardia shares are owned by institutional investors. 11.8% of Appili Therapeutics shares are owned by company insiders. Comparatively, 20.0% of BioCardia shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

BioCardia beats Appili Therapeutics on 7 of the 12 factors compared between the two stocks.

About Appili Therapeutics

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.

About BioCardia

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.